I

Innocan Pharma Corp
CNSX:INNO

Watchlist Manager
Innocan Pharma Corp
CNSX:INNO
Watchlist
Price: 7 CAD -8.38% Market Closed
Market Cap: CA$31.5m

Operating Margin

-3.4%
Current
Improving
by 31.8%
vs 3-y average of -35.2%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-3.4%
=
Operating Income
$-1.3m
/
Revenue
$27m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-3.4%
=
Operating Income
CA$-1.3m
/
Revenue
$27m

Peer Comparison

Country Company Market Cap Operating
Margin
IL
Innocan Pharma Corp
CNSX:INNO
31.5m CAD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Eli Lilly and Co
NYSE:LLY
1T USD
Loading...
UK
Dechra Pharmaceuticals PLC
F:1PK
5.1B EUR
Loading...
US
Johnson & Johnson
NYSE:JNJ
529.7B USD
Loading...
US
Abbvie Inc
NYSE:ABBV
387.5B USD
Loading...
CH
Roche Holding AG
SIX:ROG
275.3B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
210.3B GBP
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK
Loading...
CH
Novartis AG
SIX:NOVN
221.9B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
269.1B USD
Loading...

Market Distribution

In line with most companies in Israel
Percentile
32nd
Based on 734 companies
32nd percentile
-3.4%
Low
-84 760% — -5.8%
Typical Range
-5.8% — 10.9%
High
10.9% — 23 869.1%
Distribution Statistics
Israel
Min -84 760%
30th Percentile -5.8%
Median 4%
70th Percentile 10.9%
Max 23 869.1%

Innocan Pharma Corp
Glance View

Market Cap
31.5m CAD
Industry
N/A

InnoCan Pharma Corp. focuses on the development and sale of CBD-integrated pharmaceuticals including topical treatments for relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The company operates through three distinct operating segments: Research, Development, Marketing, Distribution and sales of InnoCan-branded over the counter (OTC) pharmaceutical products; Research and Development of Non-pharmaceutical products for third parties and Research and Development of hydrogels containing liposomes intended for licensing or sale to third party pharmaceutical corporations for manufacturing, distribution and sales. The firm is developing an OTC topical treatments product line and new platform to facilitate the targeted controlled administration of cannabinoids via injection.

INNO Intrinsic Value
12.74 CAD
Undervaluation 45%
Intrinsic Value
Price
I
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-3.4%
=
Operating Income
$-1.3m
/
Revenue
$27m
What is Innocan Pharma Corp's current Operating Margin?

The current Operating Margin for Innocan Pharma Corp is -3.4%, which is above its 3-year median of -35.2%.

How has Operating Margin changed over time?

Over the last 3 years, Innocan Pharma Corp’s Operating Margin has increased from -358.1% to -3.4%. During this period, it reached a low of -358.1% on Sep 30, 2022 and a high of 1% on Mar 31, 2025.

Back to Top